Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) is a clinical-stage gene editing company focused on developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS platform. This summary covers the quarterly period ended June 30, 2025 (Q2 2025). The company operates as a single segment and is classified as a smaller reporting company. In July 2025, the company initiated operating efficiency measures to reduce annual expenses and extend its cash runway.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $18,000 | $49,898,000 | $47,000 | $67,482,000 |
| Net Loss | $(23,520,000) | $32,749,000 (Income) | $(44,085,000) | $41,337,000 (Income) |
| Operating Expenses | $21,895,000 | $25,752,000 | $44,036,000 | $47,523,000 |
| Cash & Equivalents | $62,242,000 (as of June 30, 2025) | |||
| Total Cash, Equivalents & Restricted Cash | $84,806,000 (as of June 30, 2025) | |||
| Debt (Term Loan) | $22,500,000 (Principal Outstanding) | |||
| Accumulated Deficit | $(526,549,000) (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Collapse: Revenue dropped significantly from $49.9 million in Q2 2024 to $18,000 in Q2 2025. The prior year included $48.2 million in revenue from the conclusion of the Prevail Therapeutics agreement, which is no longer active.
- Profitability Shift: The company swung from a net income of $32.7 million in Q2 2024 to a net loss of $23.5 million in Q2 2025. The prior year's income was heavily influenced by an $18.2 million gain on the change in fair value of warrant liabilities and significant collaboration revenue.
- Expense Management: Total operating expenses decreased by $3.9 million year-over-year for the quarter, driven by a $4.5 million reduction in R&D expenses. This decrease was primarily due to lower manufacturing and toxicology costs for the PBGENE-HBV program as it transitioned to clinical trials, partially offset by increased costs for the PBGENE-DMD program.
- Cash Position: Cash and cash equivalents decreased by $23.7 million during the six months ended June 30, 2025, compared to an increase of $6.9 million in the same period in 2024, reflecting the cessation of large upfront collaboration payments and continued operational burn.
Guidance, Outlook, and Risks
- Clinical Progress:
- PBGENE-HBV (Hepatitis B): Phase 1 ELIMINATE-B trial data for Cohort 1 (lowest dose) showed the treatment was well-tolerated with substantial HBsAg reductions. Cohort 2 dosing is ongoing, and Cohort 3 initiation was recommended.
- PBGENE-DMD (Duchenne Muscular Dystrophy): Received Rare Pediatric Disease and Orphan Drug designations in mid-2025. Preclinical data showed significant functional improvement. An IND/CTA filing is targeted for the end of 2025.
- PBGENE-3243: Development has been paused to prioritize lead programs.
- Liquidity and Runway: Management estimates that existing cash, expected receipts, and ATM facility availability will fund operations into the second half of 2027. This runway supports potential Phase 2 studies for PBGENE-HBV and pivotal studies for PBGENE-DMD pending data readouts.
- Cost Reductions: In July 2025, the company initiated an operating efficiency program, including employment and expense reductions, to extend its cash runway.
- Key Risks:
- Funding Needs: The company has an accumulated deficit of $526.5 million and expects to incur losses for the foreseeable future. It is subject to the "Baby Shelf Rule," limiting the amount of capital it can raise via its ATM facility until its public float exceeds $75 million.
- Regulatory Uncertainty: As a novel genome editing technology, regulatory pathways are complex and evolving. Clinical trial outcomes are uncertain.
- Collaboration Dependence: Future revenue relies heavily on milestone payments from partners (e.g., TG Therapeutics, Novartis) and the success of their respective programs.
Investor Verification Checklist
- Cash Runway Validation: Verify the assumptions behind the "second half of 2027" cash runway estimate, specifically regarding the timing of potential milestone payments from TG Therapeutics and Novartis.
- Debt Covenants: Review the terms of the $22.5 million Banc of California term loan, specifically the requirement to maintain a cash security account equal to the outstanding principal, which restricts liquidity.
- Revenue Recognition: Confirm the status of deferred revenue related to the TG Therapeutics agreement and the likelihood of recognizing the $7.5 million clinical milestone payment.
- Capital Raising Constraints: Assess the impact of the "Baby Shelf Rule" on the company's ability to raise capital quickly if clinical data readouts are delayed or negative.
- Warrant Liability: Monitor the fair value adjustments of the $2.8 million warrant liability, as fluctuations can significantly impact reported net income/loss without affecting cash flow.